Profil
Mr. Laufert was previously employed as a Principal by GCP Fund III Corp., a Principal by Guilford Pharmaceuticals, Inc., and a Principal by Pfizer Inc.
Mr. Laufert received his undergraduate degree from Mount St. Mary's College, a graduate degree from Georgetown University, and an MBA from Johns Hopkins University.
Anciens postes connus de Michael D. Laufert
| Sociétés | Poste | Fin |
|---|---|---|
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | - |
| GCP Fund III Corp. | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Formation de Michael D. Laufert
| The Johns Hopkins University | Masters Business Admin |
| Georgetown University | Graduate Degree |
| Mount Saint Mary's University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
| GCP Fund III Corp. |
